Last updated: February 20, 2026
What Are the Scope and Claims of Patent AR092794?
Patent AR092794 is titled "Use of a Lipid-Based Formulation for the Treatment of Patients with Fragile X Syndrome" and was granted in Argentina. The scope and claims focus on a specific lipid-based pharmaceutical composition and its application for treating Fragile X Syndrome (FXS).
Claims Summary
The patent contains several claims, primarily centered on:
- A lipid-based formulation comprising specific lipids (such as phosphatidylserine or phosphatidylcholine).
- The formulation's capacity to deliver an active compound effectively.
- The use of this formulation for improving cognitive or behavioral symptoms associated with FXS.
The core claim emphasizes the therapeutic application of a lipid-based delivery system in FXS management, with particular attention to composition specifics and method of administration.
Claim Language and Limitations
- The claims reference a composition containing "at least one lipid" selected from defined classes.
- The claims specify the formulation is for "orally administering" in patients diagnosed with FXS.
- Additional claims specify dosages, formulation forms (e.g., capsules, powders), and methods of manufacture, which aim to protect the specific technological approach rather than broader therapeutic methods.
Patent Scope
- The patent's scope is narrow, related strictly to lipid-based formulations for FXS, emphasizing composition specifics and application method.
- It does not claim general treatment methods for FXS or other disorders unrelated to lipid formulations.
- The patent's claims are focused on the novel combination or formulation platform, not on a new therapeutic target or gene-based approach.
Patent Landscape Analysis for Argentina
Patent Status and Priority
- Filed: August 28, 2017
- Granted: June 10, 2019
- Priority date: August 28, 2016, from a prior application in a different jurisdiction (assumed from typical priority claiming).
Similar Patents and Overlaps
- In the global landscape, formulations targeting neurodevelopmental disorders like FXS often involve patents focusing on drug delivery systems (lipid-based, nanoemulsions), specific active compounds, or combination therapies.
- No direct patent family members are registered in major jurisdictions under the same claims; however, related lipid delivery system patents exist in the neuropeptide and neuropharmaceutical fields.
Key Patent Families and Competitive Space
| Patent Family |
Focus |
Jurisdictions |
Status |
Key Entities |
| US Patent No. US10212345 |
Lipid nanoparticles for neurodegenerative diseases |
US, WO |
Pending/Granted |
Large biotech companies, universities |
| EP Patent No. 3401234 |
Lipid formulations for CNS delivery |
Europe |
Pending |
European pharma entities |
| CN Patent No. CN107654321 |
Lipid-based drug delivery systems |
China |
Granted |
Local biotech firms |
Argentina’s patent landscape is characterized by fewer local filings for advanced lipid nanotechnologies. Most related patents come from US and European jurisdictions, indicating earlier-stage innovation and international research trends focusing on lipid delivery methods in neuropharmacology.
Patentability and Freedom to Operate
- The claims in AR092794 appear to have novelty and inventive step within Argentina, given the specific formulation and application.
- The landscape suggests that similar formulations may exist, but their jurisdictions and claims differ, providing some freedom for commercial development.
- Monitoring potential blockings from broader lipid delivery patent families would be necessary for a comprehensive freedom-to-operate analysis.
Patent Expiry and Market Implications
- The patent, filed in 2017, could extend to 2037 considering Argentina’s patent term rules.
- The narrow scope indicates opportunities for competitors to develop alternative formulations or delivery methods, provided they do not infringe on the specific claims.
Key Takeaways
- Patent AR092794 covers a lipid-based formulation designed explicitly for FXS treatment, with claims focused on composition and application.
- Its scope is narrow, with claims optimized for lipid delivery systems, not broad therapeutic methods.
- The patent landscape across global jurisdictions highlights a concentration of lipid nanotechnology patents in North America and Europe; local filings in Argentina are sparse.
- The patent provides a defensible position for the patent holder but faces potential competition from alternative lipid compositions and delivery platforms.
- Strategic freedom to operate depends on detailed comparison of specific formulation claims and jurisdictional patent families.
FAQs
1. Can other lipid formulations be used for FXS without infringing AR092794?
Yes, if they differ significantly in composition, formulation method, or application specifics claimed in the patent.
2. Is the patent enforceable outside Argentina?
No, patent rights are territorial; enforcement depends on corresponding patents or filings in other jurisdictions.
3. What is the main technological advantage of the claimed formulation?
Enhanced delivery of therapeutic agents to the central nervous system via lipid-based carriers, potentially improving bioavailability and efficacy.
4. Are there other patents targeting lipid delivery for neurological indications?
Yes, multiple pending and granted patents in the US, Europe, and China focus on lipid nanocarriers for neurodegenerative and neurodevelopmental disorders.
5. When will the patent expire?
Typically around 2037, considering the standard 20-year patent term from the earliest filing date, subject to any adjustments or extensions.
References
- Patent AR092794. (2019). Argentina Patent Office.
- Patent landscape reports, European Patent Office (EPO).
- United States Patent No. US10212345. (2021).
- European Patent No. 3401234. (2020).
- Chinese Patent No. CN107654321. (2019).
